Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Revue D'Epidemiologie Et De Sante Publique|April 13, 2006
[Directly observed therapy (DOT): from tuberculosis to HIV]N Machouf, R-G Lalonde
Social Science & Medicine (1982)|July 29, 1998
What does quality mean to lay people? Community perceptions of primary health care services in GuineaS Haddad, P Fournier, N Machouf, et al.
HIV Medicine|July 17, 2015
Predictors of interest in taking pre-exposure prophylaxis among men who have sex with men who used a rapid HIV-testing site in Montreal (Actuel sur Rue)B Lebouché, K Engler, N Machouf, et al.
International Journal of STD & AIDS|November 17, 2007
Inadequate adherence to antiretroviral treatment and prevention in hospital and community sites in Burkina Faso and Mali: a study by the ATARAO groupS Ag Aboubacrine, P Niamba, C Boileau, et al.
Journal of Medical Virology|March 24, 2006
Effects of drug resistance on viral load in patients failing antiretroviral therapyN Machouf, R Thomas, V K Nguyen, et al.
HIV Medicine|February 28, 2009
Impact of a modified directly administered antiretroviral treatment intervention on virological outcome in HIV-infected patients treated in Burkina Faso and MaliC M Pirkle, C Boileau, V-K Nguyen, et al.
HIV Medicine|May 26, 2010
Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patientsS Lambert-Niclot, N Machouf, G Peytavin, et al.
HIV Medicine|December 6, 2013
Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapyP Ndumbi, J Gillis, J Raboud, et al.
HIV Medicine|September 2, 2014
Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in CanadaH Samji, T E Taha, D Moore, et al.
HIV Clinical Trials|April 19, 2012
Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapyJ Raboud, A Anema, D Su, et al.
Pageof 2